MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe

Completed
Conditions
Atrial Fibrillation
First Posted Date
2014-09-16
Last Posted Date
2017-12-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
36573
Registration Number
NCT02240654
Locations
🇪🇸

1160.144.1 Boehringer Ingelheim Investigational Site, Barcelona, Spain

Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

First Posted Date
2014-09-15
Last Posted Date
2014-09-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
79
Registration Number
NCT02239835

Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria

Completed
Conditions
Urticaria
Interventions
Drug: Alesion®
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
122
Registration Number
NCT02238249

Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Atrovent® inhalets
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
346
Registration Number
NCT02238171

Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Atrovent® Inhalation Solution
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
477
Registration Number
NCT02238197

Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Atrovent® Inhaletten
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
660
Registration Number
NCT02238145

Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals

Completed
Conditions
Hypertension
Interventions
Drug: Telmisartan
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2318
Registration Number
NCT02238262

Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet

Completed
Conditions
Rhinitis, Allergic, Perennial
Interventions
Drug: Alesion®
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2001
Registration Number
NCT02238223

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: Tipranavir low dose
Drug: Tipranavir high dose
Drug: Ritonavir
Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Drug: Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
41
Registration Number
NCT02238314

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Tiotropium + formoterol combination
Drug: Tiotropium
Drug: Formoterol
First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
74
Registration Number
NCT02238119
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy